We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 229

Industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • August 6 2014

Health Canada has published a Policy on DrugMedical Device Combination Product Decisions. Health Canada has published a Revision to an

Intellectual property weekly abstracts bulletin Week of July 14

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 17 2014

Allianz Asset Management of America L.P. (“AAMA”) and Allianz Global Investors of America L.P. (“AGIA”) appealed two decisions of the Trade-marks

Other industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 5 2014

The amendments to the Patent Rules and Trade-marks Regulations affecting both patent and trade-mark agents came into effect on May 1, 2014. The

Ontario regulation prohibiting private label generic drugs declared ultra vires

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 16 2011

In 2010, regulations were made pursuant to each of the Ontario Drug Benefit Act (ODBA) and the Drug Interchangeability and Dispensing Fee Act (DIDFA

Pharmacies not permitted to sell “private label” generic drugs

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 4 2012

The Government of Ontario appealed from two Orders of the Divisional Court declaring that sections of provincial regulations banning pharmacies from selling “private label” generic drugs are ultra vires and of no force and effect

Court grants motion to reopen trial and admit new evidence

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 27 2011

The Federal Court granted leave to reopen the trial and admit new evidence in a matter under reserve, in which no reasons or judgement have issued

Interlocutory injunction denied

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 29 2011

This was a motion for an interlocutory injunction

Other industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 6 2013

The PMPRB has announced a Monitoring and Evaluation Plan for the Major Changes in the Guidelines. CIPO has announced a new PCT-Patent Prosecution

Appeal upholds dismissal of request to amend pleadings due to proximity to trial

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 4 2014

This case concerns an appeal of a motion to amend pleadings in the s. 8 case described above. The motion had originally been brought three months

The Court of Appeal sends s.8 case back to trial judge for redetermination

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 26 2012

The Federal Court of Appeal (FCA) has granted Apotex’ appeal and sent a case considering s. 8 of the Patented Medicines (Notice of Compliance) Regulations (the Regulations) back to the Trial Judge for redetermination